APOE-mediated immunometabolic reprogramming of macrophages drives lipid delivery to tumor cells in clear-cell renal cell carcinoma — a metabolic checkpoint
RNA-seq (gene expression) · human · 9 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Kidney cancerThis series is part of our curated briefing on it.
- Samples
- 9 samples: 7 distinct titles, 1 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE301221_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1284296 and SRA study SRP596215. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 9 sample titles: 7 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9078282 Ma Ctr-1
- GSM9078283 Ma Ctr-2
- GSM9078284 Ma Ctr-3
- GSM9078285 Ma APOEhi.(1)
- GSM9078286 Ma APOEhi.(2)
- GSM9078287 Ma APOEhi.(3)
- GSM9078288 Ma APOElo.(1)
- GSM9078289 Ma APOElo.(2)
- GSM9078290 Ma APOElo.(3)
- GSE216495 Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma 36 samples same disease briefing · shares checkpoint
- GSE214635 The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis 18 samples same disease briefing
- GSE216494 Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro 12 samples same disease briefing
- GSE174740 Drug repurposing identifies a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma 11 samples same disease briefing
- GSE223688 SETD2 loss sensitizes kidney cancer cells to DNA hypomethylating agents 6 samples same disease briefing
- GSE193006 Transcriptome RNA sequencing data of sarcomatoid renal cell carcinoma cell line SRCC and its subclones with different phenotypes. 5 samples same disease briefing
- GSE17895 Somatic Mutation Screen of Clear Cell RCC 160 samples same disease briefing
- GSE15641 Gene signatures of progression and metastasis in renal cell cancer 92 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.